Fig. 4

MKK3 upregulation correlates with poor survival of Black or African American breast cancer patients. a The heatmap shows the frequency of genomic alterations of MKK3 in different cancer types. The percent of samples with MKK3 overexpression or amplification is shown with red color ranging from the smallest (light color) to the highest (strong color) values. The frequency of MKK3 mutations is indicated with the gradient of green color. MKK3 underexpression or deletion is highlighted in blue color. b MKK3 upregulation does not correlate with poor survival of the pooled cohort of breast cancer patients. c MKK3 deletions observed in 0.5% of breast cancer patient correlates with decreased patient survival. d Distribution of MKK3 upregulation in Black/African American, Asian, and White cohorts of breast cancer patients. e The upregulation of MKK3 does not correlate with decreased survival of White breast cancer patients. f The upregulation of MKK3 does not correlate with decreased survival of Asian breast cancer patients. g The upregulation of MKK3 correlates with poor survival of Black/African American breast cancer patients. h The upregulation of MKK3 correlates with decreased survival of Black/African American triple-negative breast cancer patients. i The upregulation of MKK3 does not correlate with poor survival of White TNBC patients. j Upregulation of p38 (MAPK14) does not correlate with poor survival of Black/African American breast patients. k In contrast to MKK3, the upregulation of MAPK14 does not correlate with decreased survival of TNBC Black/African American patients